Cargando…

Antipsychotic Drugs Opposite to Metabolic Risk: Neurotransmitters, Neurohormonal and Pharmacogenetic Mechanisms Underlying with Weight Gain and Metabolic Syndrome

Important sources of metabolic diseases such as obesity and metabolic syndrome are significantly more prevalent in patients treated with antipsychotic drugs than the general population and they not only reduce the quality of life but also significantly reduce the life expectancy, being important ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Milano, Walter, De Rosa, Michele, Milano, Luca, Capasso, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722531/
https://www.ncbi.nlm.nih.gov/pubmed/23894259
http://dx.doi.org/10.2174/1874205X01307010023
_version_ 1782278203607351296
author Milano, Walter
De Rosa, Michele
Milano, Luca
Capasso, Anna
author_facet Milano, Walter
De Rosa, Michele
Milano, Luca
Capasso, Anna
author_sort Milano, Walter
collection PubMed
description Important sources of metabolic diseases such as obesity and metabolic syndrome are significantly more prevalent in patients treated with antipsychotic drugs than the general population and they not only reduce the quality of life but also significantly reduce the life expectancy, being important risk factors for cardiovascular disease. The pathogenic mechanisms underlying these events are not entirely clear they are complex and multi-determined or not tied to a single defining event. In this review we examine the literature on the interactions of antipsychotic drugs with neurotransmitters in the brain, with pharmacogenetics hormones and peripheral mechanisms that may induce, albeit in different ways between different molecules, not only weight gain but also 'onset of major diseases such as diabetes, dyslipidemia and hypertension that are the basis of the metabolic syndrome. Today, the possible metabolic changes induced by various antipsychotic drugs and their major physical health consequences, are among the major concerns of clinicians and it is therefore necessary to monitor the main metabolic parameters to prevent or minimize any of these patients as well as the metabolism events associated with the use of antipsychotic drugs.
format Online
Article
Text
id pubmed-3722531
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Bentham Open
record_format MEDLINE/PubMed
spelling pubmed-37225312013-07-26 Antipsychotic Drugs Opposite to Metabolic Risk: Neurotransmitters, Neurohormonal and Pharmacogenetic Mechanisms Underlying with Weight Gain and Metabolic Syndrome Milano, Walter De Rosa, Michele Milano, Luca Capasso, Anna Open Neurol J Article Important sources of metabolic diseases such as obesity and metabolic syndrome are significantly more prevalent in patients treated with antipsychotic drugs than the general population and they not only reduce the quality of life but also significantly reduce the life expectancy, being important risk factors for cardiovascular disease. The pathogenic mechanisms underlying these events are not entirely clear they are complex and multi-determined or not tied to a single defining event. In this review we examine the literature on the interactions of antipsychotic drugs with neurotransmitters in the brain, with pharmacogenetics hormones and peripheral mechanisms that may induce, albeit in different ways between different molecules, not only weight gain but also 'onset of major diseases such as diabetes, dyslipidemia and hypertension that are the basis of the metabolic syndrome. Today, the possible metabolic changes induced by various antipsychotic drugs and their major physical health consequences, are among the major concerns of clinicians and it is therefore necessary to monitor the main metabolic parameters to prevent or minimize any of these patients as well as the metabolism events associated with the use of antipsychotic drugs. Bentham Open 2013-05-31 /pmc/articles/PMC3722531/ /pubmed/23894259 http://dx.doi.org/10.2174/1874205X01307010023 Text en © Milano et al.; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Milano, Walter
De Rosa, Michele
Milano, Luca
Capasso, Anna
Antipsychotic Drugs Opposite to Metabolic Risk: Neurotransmitters, Neurohormonal and Pharmacogenetic Mechanisms Underlying with Weight Gain and Metabolic Syndrome
title Antipsychotic Drugs Opposite to Metabolic Risk: Neurotransmitters, Neurohormonal and Pharmacogenetic Mechanisms Underlying with Weight Gain and Metabolic Syndrome
title_full Antipsychotic Drugs Opposite to Metabolic Risk: Neurotransmitters, Neurohormonal and Pharmacogenetic Mechanisms Underlying with Weight Gain and Metabolic Syndrome
title_fullStr Antipsychotic Drugs Opposite to Metabolic Risk: Neurotransmitters, Neurohormonal and Pharmacogenetic Mechanisms Underlying with Weight Gain and Metabolic Syndrome
title_full_unstemmed Antipsychotic Drugs Opposite to Metabolic Risk: Neurotransmitters, Neurohormonal and Pharmacogenetic Mechanisms Underlying with Weight Gain and Metabolic Syndrome
title_short Antipsychotic Drugs Opposite to Metabolic Risk: Neurotransmitters, Neurohormonal and Pharmacogenetic Mechanisms Underlying with Weight Gain and Metabolic Syndrome
title_sort antipsychotic drugs opposite to metabolic risk: neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722531/
https://www.ncbi.nlm.nih.gov/pubmed/23894259
http://dx.doi.org/10.2174/1874205X01307010023
work_keys_str_mv AT milanowalter antipsychoticdrugsoppositetometabolicriskneurotransmittersneurohormonalandpharmacogeneticmechanismsunderlyingwithweightgainandmetabolicsyndrome
AT derosamichele antipsychoticdrugsoppositetometabolicriskneurotransmittersneurohormonalandpharmacogeneticmechanismsunderlyingwithweightgainandmetabolicsyndrome
AT milanoluca antipsychoticdrugsoppositetometabolicriskneurotransmittersneurohormonalandpharmacogeneticmechanismsunderlyingwithweightgainandmetabolicsyndrome
AT capassoanna antipsychoticdrugsoppositetometabolicriskneurotransmittersneurohormonalandpharmacogeneticmechanismsunderlyingwithweightgainandmetabolicsyndrome